The connection between dasatinib and statinib

Dasatinib (Dasatinib) is a targeted drug widely used to treat chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). It is a second-generation tyrosine kinase inhibitor that mainly works by inhibiting the activity of BCR-ABL fusion protein, thus preventing the proliferation of cancer cells.

Dasatinib is the trade name of dasatinib, and they are actually the same drug. Dasatinib, as an active ingredient, was developed by a pharmaceutical company and underwent clinical trials before it received market approval and was eventually launched in China under the name Startaxel. In many cases, dasatinib refers to the drug's chemical name or ingredient, while dasatinib is its brand name in the commercial market.

The mechanism of action of dasatinib is complex. It can not only effectively inhibit BCR-ABL, but also inhibit a variety of other tyrosine kinases, such as SRC family kinases, KIT, PDGFR, etc., so it can often achieve good results in the treatment of some drug-resistant leukemia patients. This characteristic makes dasatinib show more potential in clinical applications.

Clinically, the use of dasatinib is also accompanied by certain side effects, such as edema, arrhythmia, pulmonary discomfort, etc. Therefore, physicians need to consider the patient's specific situation and conduct appropriate monitoring and management when using this drug. Typically, patients will have periodic blood tests while receiving dasatinib treatment to evaluate the drug's effectiveness and possible side effects.

Since its entry into the market, Starase has helped many patients with chronic myelogenous leukemia and acute lymphoblastic leukemia improve their quality of life and extend their survival. Through the continuous in-depth use and research of the drug, the medical community's understanding of dasatinib is also deepening, and relevant clinical guidelines and treatment plans are constantly updated to better guide doctors and patients.